| h-d2937ed0 | Microglial TREM2-Independent Pathway Activation | 0.55 | 0.60 | DAP12, SYK, PLCG2 | proposed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222543-20260402 |
| h-d69f2fdd | CNTF-JAK/STAT3 Reprogramming of Trained Microglia to Neuroprotective State | 0.55 | 0.52 | CNTFRα/GP130 → JAK1/JAK2 → p-STAT3(Y705) | proposed | 2026-04-26 | SDA-2026-04-08-gap-debate-20260406-062033-ad87c3fb |
| SDA-2026-04-02-gap-t | Synaptic Vesicle Tau Capture Inhibition | 0.55 | 0.38 | SNAP25 | proposed | 2026-04-17 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-var-297004b1d7 | Gamma-Entrained PV Interneurons Enable p-tau217-Guided Precision Dosing of lncRN | 0.55 | 0.39 | lncRNA-0021, PVALB, CREB1 | promoted | 2026-04-17 | SDA-2026-04-16-gap-pubmed-20260410-150509-76c40dac |
| h-ab3a0af5 | NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Met | 0.55 | 0.55 | PARP1, SIRT1/3, NAD+ | proposed | 2026-04-26 | SDA-2026-04-16-frontier-metabolomics-f03b09d9 |
| h-7110565d | Sensory-Motor Circuit Cross-Modal Compensation | 0.55 | 0.20 | CHAT | proposed | 2026-04-04 | SDA-2026-04-03-26abc5e5f9f2 |
| h-9d2bca0f28 | Combined p-tau217 + p-tau231 Panel Increases Specificity for Treatment Cessation | 0.55 | 0.48 | NA - Multi-biomarker diagnostic | proposed | 2026-04-25 | |
| h-var-521f97f447 | Closed-loop transcranial focused ultrasound with real-time gamma feedback to res | 0.55 | 0.82 | PVALB | promoted | 2026-04-17 | SDA-2026-04-03-26abc5e5f9f2 |
| h-528099e954 | Computational Model-Optimized TFUS Parameters for Interneuron Targeting | 0.55 | 0.48 | Hodgkin-Huxley formalism with mechanoelectrical transduction | proposed | 2026-04-28 | SRB-2026-04-28-h-var-a4975bdd96 |
| h-SDA-2026-04-26-gap | 5-HT2A/C Silencing Enables Sustained BDNF-TrkB Signaling for Spine Maintenance | 0.55 | 0.47 | 5-HT2A receptor (HTR2A), BDNF, TrkB (NTRK2), CREB | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-081101-dfe3eacb |
| h-SDA-2026-04-26-gap | Restorative Sleep Induction as the Threshold Mechanism: Dose-Dependent REM Enhan | 0.55 | 0.47 | AQP4 water channels (perivascular astrocyte end-feet), lymph | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-081101-dfe3eacb |
| h-SDA-2026-04-26-gap | Co-translational ER Targeting Defect and Lysosomal Delivery Failure | 0.55 | 0.47 | SRP54, SRP68, SRP72 (SRP components); SCARB2 (LIMP-2) | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260412-094853-199f4f1b |
| h-SDA-2026-04-26-gap | ER-Associated Degradation (ERAD) Cross-Activation | 0.55 | 0.47 | EIF2AK3 (PERK), EIF2S1 (eIF2α); HSPA5 (BiP), XBP1 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260412-094853-199f4f1b |
| h-0c189719 | Co-translational mRNA localization as a sensor for RNA granule trafficking defec | 0.55 | 0.50 | IGF2BP1 (ZBP1), TARDBP (TDP-43 in RNA granules); β-actin ACT | proposed | 2026-04-26 | SDA-2026-04-10-gap-debate-20260410-075000-7396040a |
| h-7857b01b | CD300f Immune Checkpoint Activation | 0.54 | 0.30 | CD300F | proposed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-7c3c0f40 | Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromatin Remodeling | 0.54 | 0.50 | SIRT1, FOXO3, NRF2, TFAM | proposed | 2026-04-04 | SDA-2026-04-03-gap-crispr-neurodegeneration-20260402 |
| h-fdaae8d9 | Trans-Synaptic Adhesion Molecule Modulation | 0.54 | 0.34 | NLGN1 | proposed | 2026-04-02 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-c9486869 | HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor | 0.54 | 0.45 | DNAJB6 | proposed | 2026-04-03 | SDA-2026-04-01-gap-9137255b |
| h-019ad538 | Temporal Decoupling via Circadian Clock Reset | 0.54 | 0.70 | CLOCK | debated | 2026-04-02 | sda-2026-04-01-gap-009 |
| h-b3f9d8eb | HCN1-Selective Blockade Normalizes Thalamic Rebound Bursting in P/Q Channel Defi | 0.54 | 0.71 | HCN1 | proposed | 2026-04-14 | SDA-2026-04-14-gap-pubmed-20260410-181156-feec7bd3 |
| h-var-e399c10fff | TREM2-GluN2B Circuit: Microglial Control of Thalamocortical Oscillations and Gly | 0.54 | 0.67 | TREM2 | proposed | 2026-04-21 | SDA-2026-04-03-26abc5e5f9f2 |
| h-var-9d621130e8 | Circadian Epigenetic Ketone Synchronization Protocol | 0.54 | 0.47 | CLOCK/BMAL1 | proposed | 2026-04-20 | SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 |
| h-var-99256f9f61 | Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extracellular Vesicle Deli | 0.54 | 0.39 | CSF p-tau217 (biomarker), lncRNA-0021, astrocyte-derived ext | promoted | 2026-04-17 | SDA-2026-04-16-gap-pubmed-20260410-150509-76c40dac |
| h-909ba8c750 | Epigenetic Reprogramming Required for Late-Stage Interventions (OSKM) | 0.54 | 0.48 | DNA methylation machinery (DNMTs), H3K27ac modifiers (p300/C | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-7a6cf14e |
| h-var-1647fd2642 | Real-time closed-loop transcranial focused ultrasound targeting PV interneurons | 0.54 | 0.71 | PVALB | promoted | 2026-04-21 | SDA-2026-04-03-26abc5e5f9f2 |
| h-c69709f5 | Astrocyte Metabolic Memory Reprogramming | 0.54 | 0.60 | SIRT1 | proposed | 2026-04-12 | SDA-2026-04-04-gap-debate-20260403-222618-e6a431dd |
| hyp_test_3aeaba02 | Test: TREM2 enhances amyloid clearance | 0.54 | 0.30 | TREM2 | archived | 2026-04-04 | test-hypothesis-fixtures-v1 |
| hyp_test_69d36bcc | Test: TREM2 enhances amyloid clearance | 0.54 | 0.30 | TREM2 | archived | 2026-04-04 | test-hypothesis-fixtures-v1 |
| hyp_test_fd653a9e | Test: TREM2 enhances amyloid clearance | 0.54 | 0.30 | TREM2 | archived | 2026-04-04 | test-hypothesis-fixtures-v1 |
| hyp_test_51bcc306 | Test: TREM2 enhances amyloid clearance | 0.54 | 0.30 | TREM2 | archived | 2026-04-04 | test-hypothesis-fixtures-v1 |
| hyp_test_59e50f48 | Test: TREM2 enhances amyloid clearance | 0.54 | 0.30 | TREM2 | archived | 2026-04-04 | test-hypothesis-fixtures-v1 |
| h-57b37c06d6 | Low-Intensity tFUS Modulation of EC-DG/EC-CA1 Perforant Path Synaptic Function | 0.54 | 0.58 | Piezo1 (preclinical validation only); BDNF/TrkB pathway | proposed | 2026-04-28 | SRB-2026-04-28-h-var-b7e4505525 |
| h-923e06cc90 | Cross-Seeding: Gut Microbiome-Derived Bacterial Curli and Fungal Amyloid Synergi | 0.54 | 0.60 | TLR2, TLR1, IRF5, IRF4, CsgA, csgABC operon | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260425-225305 |
| h-8a1a418d72 | Soluble CX3CL1 cleavage by ADAM proteases disengages fractalkine signaling, remo | 0.54 | 0.62 | CX3CL1, CX3CR1, ADAM10, ADAM17 | proposed | 2026-04-22 | SDA-2026-04-02-gap-synaptic-pruning-microglia |
| h-a0a251cfcf | H5: Olfactory System as a Toxicant Funnel into Layer II | 0.54 | 0.48 | NLRP3, CX3CR1, TLR4 | proposed | 2026-04-22 | SDA-2026-04-02-gap-ec-layer2-vulnerability |
| h-6298061b6e | circHomer1a Restoration as Neuroprotective Strategy in Synaptic Decline | 0.54 | 0.68 | circHomer1a, miR-1961, HOMER1 | proposed | 2026-04-22 | SDA-2026-04-02-gap-2026-04-01-gap-006 |
| h-10ac959b07 | N-acetylation Deficiency as Novel Metabolic Vulnerabilities in Sporadic ALS | 0.54 | 0.62 | NAA10, NAA20, NAA80 | proposed | 2026-04-22 | SDA-2026-04-02-gap-2026-04-01-gap-006 |
| h-99dd982b52 | Transient OCT4/SOX2/KLF4/c-MYC Expression Reverses Epigenetic Age and Restores V | 0.54 | 0.65 | OCT4/SOX2/KLF4/c-MYC (OSKM) | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-060512 |
| h-2a43bfc5b1 | TAM Receptor (MERTK/AXL) Cross-Regulation | 0.54 | 0.52 | MERTK, AXL, TYRO3, PROS1 (Protein S), GAS6 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755 |
| h-6ae3f31128 | H6: Epigenetic Reset via APOE4→APOE3 Conversion Reverses Senescence | 0.54 | 0.45 | APOE; HDAC1; EZH2 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-5d7b9dc0 |
| h-cbd5cd6b7f | BAG3-Mediated Hsp70 Substrate Redistribution | 0.54 | 0.52 | HSPA1A/Hsp70, BAG3 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062150-a6cc7467 |
| h-389692c80b | P2Y6R activation by UDP from damaged neurons drives microglial phagocytosis and | 0.54 | 0.58 | P2RY6 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062052-946439a8 |
| h-0d030c455b | Systemic IL-6–STAT3–Hepatic C3 Axis and BBB-Mediated Complement Translocation | 0.54 | 0.42 | IL6; STAT3; C3 | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062128-afe67892 |
| h-edfd6c89 | Dual-Phase Medium-Chain Triglyceride Intervention | 0.54 | 0.70 | HMGCS2/CPT1A | promoted | 2026-04-12 | SDA-2026-04-04-gap-debate-20260403-222618-e6a431dd |
| h-var-93e3ef09b3 | Microglial Exosome-Mediated Tau Propagation | 0.54 | 0.78 | MAPT | proposed | 2026-04-12 | SDA-2026-04-03-26abc5e5f9f2 |
| h-8986b8af | Lysosomal Membrane Repair Enhancement | 0.54 | 0.62 | CHMP2B | debated | 2026-04-02 | sda-2026-04-01-gap-011 |
| h-5669af0f | Ferroptosis as Disease-Modifying Amplifier | 0.54 | 0.55 | | proposed | 2026-04-18 | SDA-2026-04-18-gap-debate-20260417-032952-48bdcbea |
| h-ebfa8ea3 | ABCA7-TREM2 Co-Targeting for Microglial Lipid Handling | 0.54 | 0.55 | ABCA7 + TREM2 (combinatorial) | proposed | 2026-04-14 | SDA-2026-04-14-gap-pubmed-20260410-180532-e8930cb8 |
| h-62e56eb9 | Glymphatic System-Enhanced Antibody Clearance Reversal | 0.54 | 0.65 | AQP4 | debated | 2026-04-02 | sda-2026-04-01-gap-008 |
| h-c98263c726 | Excitatory/Inhibitory Balance Reversal via Somatostatin Interneuron Rescue | 0.54 | 0.52 | SST | proposed | 2026-04-28 | SDA-2026-04-28-gap-methodol-20260427-041425-9e73b245 |